Older Breast Cancer Patients Require Special Consideration
Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.
Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer
The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.
Ovarian Suppression Individualization Warranted in Breast Cancer
Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.
Multigene Testing Adds Complexity to Decision Making Process
Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.
IBM's Watson has Potential Partnership With Oncologists
Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.
"Opioid Epidemic" Increases Challenge of Treating Cancer Pain
Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.
Physicians on the Offense: Get Organized to Thrive in This Payment Arena
The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.
Deliver Androgen Blockade at Prostate Cancer Cells to Achieve Castrate Levels
Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.
Crawford Questions ADT Standards, Approaches in Prostate Cancer
E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Both Gastric and Breast HER2 Scoring Algorithms Applicable in mCRC Testing
Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC
2 Clarke Drive Cranbury, NJ 08512